Editas Medicine, Inc. (EDIT) Social Stream



Editas Medicine, Inc. (EDIT): $5.46

0.14 (-2.50%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add EDIT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#117 of 359

in industry

EDITAS MEDICINE INC (EDIT) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering EDIT.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-09 13 $80 $30 $54.909 $9.54 475.57%
2022-01-06 12 $80 $24 $52.2 $9.54 447.17%
2022-01-31 12 $80 $16 $51.4 $9.54 438.78%
2022-02-25 12 $80 $16 $46.4 $9.54 386.37%
2022-02-28 12 $80 $16 $43.7 $9.54 358.07%
2022-04-12 11 $80 $17 $41.888 $9.54 339.08%
2022-04-26 11 $80 $17 $41.111 $9.54 330.93%
2022-05-05 10 $80 $15 $37.333 $9.54 291.33%
2022-05-09 10 $80 $15 $37.111 $9.54 289%
2022-05-24 11 $80 $8 $36.222 $9.54 279.69%
2022-08-05 11 $80 $8 $30.1 $9.54 215.51%
2022-08-19 11 $80 $8 $30.444 $9.54 219.12%
2022-10-12 12 $80 $8 $29.2 $9.54 206.08%
2022-10-24 12 $80 $8 $27.818 $9.54 191.59%
2022-11-02 12 $80 $8 $27.545 $9.54 188.73%
2022-11-03 14 $80 $8 $25.666 $9.54 169.04%
2022-11-08 14 $80 $8 $25.25 $9.54 164.68%
2022-11-18 14 $43 $7 $20.083 $9.54 110.51%
2022-12-06 14 $35 $7 $16.166 $9.54 69.45%
2022-12-13 16 $35 $7 $15.153 $9.54 58.84%
2023-01-04 16 $36 $7 $16.642 $9.54 74.44%
2023-01-10 16 $36 $6 $16.571 $9.54 73.7%
2023-01-16 16 $36 $6 $15.142 $9.54 58.72%
2023-01-23 16 $36 $7 $15.214 $9.54 59.48%
2023-01-27 16 $36 $7 $15.142 $9.54 58.72%
2023-02-01 17 $36 $7 $15.133 $9.54 58.63%
2023-02-22 17 $36 $7 $15.2 $9.54 59.33%
2023-04-12 17 $30 $7 $13.666 $9.54 43.25%
2023-05-09 17 $30 $7 $13.714 $9.54 43.75%
2023-06-06 16 $30 $7 $13.714 $9.54 43.75%
2023-06-07 16 $30 $7 $14.307 $9.54 49.97%
2023-06-08 16 $30 $7 $13.785 $9.54 44.5%
2023-06-13 16 $30 $7 $14 $9.54 46.75%
2023-06-21 16 $30 $7.001 $14.066 $9.54 47.44%
2023-08-03 16 $30 $7.001 $13.857 $9.54 45.25%
2023-08-11 15 $30 $7 $13.571 $9.54 42.25%
2023-09-29 15 $30 $7 $14.153 $9.54 48.35%
2023-10-09 15 $30 $7 $14.142 $9.54 48.24%
2023-11-06 15 $30 $7 $14.076 $9.54 47.55%
2023-11-10 16 $30 $7 $13.846 $9.54 45.14%
2023-12-11 16 $30 $7 $14.5 $9.54 51.99%
2023-12-15 16 $30 $7 $14.916 $9.54 56.35%

The Trend in the Analyst Price Target


EDIT's average price target has moved up $1.37 over the prior 33 weeks.

EDIT reports an average of 59.02% for its upside potential over the past 48 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-01-27 16 36 7 15.142 9.57 58.22%
2023-02-01 17 36 7 15.133 10.41 45.37%
2023-06-08 16 30 7 13.785 9.60 43.59%
2023-11-06 15 30 7 14.461 8.31 74.02%
2023-11-06 15 30 7 14.142 8.31 70.18%

EDIT Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.11 7 1 7 0 0 16

The Trend in the Broker Recommendations


Over the past 31 weeks, EDIT's average broker recommendation rating improved by 0.47.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • EDIT has a lower variance in analysts' estimates than -5610.86% of all US stocks.
  • To contextualize these metrics, consider that out of stocks in the mid market cap category, EDITAS MEDICINE INC's number of analysts covering the stock is higher than 5321.26% of them.
  • In terms of how EDITAS MEDICINE INC fares relative to stocks in the mid market cap category, note that its upside potential (average analyst target price relative to current price) is greater than 4510.86% of that group.
  • EDITAS MEDICINE INC's average analyst price target is higher than 1964.62% of stocks in the mid market cap category.

Stocks similar to EDITAS MEDICINE INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are FATE, NSTG, and SGMO.

Is EDIT a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!